Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 45Head & Neck 35Thoracic 13Gynecologic 9CNS 5Other solid neoplasm 3Tumor-Agnostic 2Genitourinary 2Breast 1

Conditions

Breast Neoplasms 1

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 468Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × nimotuzumab × Breast × Clear all
NCT01939054 2015-06-04

Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients

ChineseAMS

Phase 2 Unknown
90 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡